| Released | Contributor | Author | Title | Pages | Price |
|---|
| Jun 19, 2013 | Stock Traders Daily | Thomas H Kee Jr. | Trading Report for (BMY). A detailed report, including free correlated market analysis, and updates. | 5 | $57.50 | | Jun 18, 2013 | New Constructs, LLC | N/A | BMY: Due Diligence Review: Forensic Earnings and Valuation | 13 | $25 | | Jun 18, 2013 | Thomson Reuters Stock Report | StockReports + Research Department | Thomson Reuters Stock Report - BRISTOL-MYERS SQUIBB COMPANY (BMY-N) | 12 | $25 | | Jun 18, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Large CAP Pharma | 17 | $195.50 | | Jun 17, 2013 | Datamonitor | Datamonitor PLC | Bristol-Myers Squibb Company | 72 | $175 | | Jun 17, 2013 | Edison Investment Research | Mr. Robin Davison, Dr. Mick Cooper, Luke Poloniecki | BIOALLIANCE PHARMA - STAND AND DE-LIVA | 12 | $10 | | Jun 17, 2013 | Wright Reports | N/A | Wright Investors Service Comprehensive Report for Bristol-Myers Squibb Company | 43 | $494.50 | | Jun 17, 2013 | Stock Traders Daily | Thomas H Kee Jr. | The Investment Rate - a measure of investment demand. | 43 | $494.50 | | Jun 17, 2013 | Alpha Street Research | Hunter Orr | BMY - Bristol-Myers Squibb Co - Downgraded to a Sell - Company Analysis and ASR Ranking Report | 9 | $24 | | Jun 16, 2013 | Pechala's Reports | Lubomir Pechala | BRISTOL MYERS SQUIBB CO (BMY) - REPORT FOR ACTIVE TRADERS | 1 | $25 |
|
View All Reports for BMY ... |
|
|
0.80(1.71%) Jun 19, 4:00PM EDT|After Hours
:
46.30